Write in a clean editor, then format for Immunological Medicine in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Immunological Medicine is a peer-reviewed journal published by Taylor & Francis, covering Systemic Lupus Erythematosus Research, Rheumatoid Arthritis Research and Therapies, Immune Cell Function and Interaction.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Immunological Medicine 12 (3): 45–58.
Formats any DOI in Immunological Medicine style. No sign-up. |
| Publishes research in | Systemic Lupus Erythematosus Research Rheumatoid Arthritis Research and Therapies Immune Cell Function and Interaction Immunodeficiency and Autoimmune Disorders Autoimmune and Inflammatory Disorders Research |
| ISSN | 2578-5826 |
| Citation impact (2-yr) | 1.95 |
| h-index | 30 |
| i10-index | 97 |
| Total citations | 3,396 |
| Open access | Yes |
| Top institutions publishing here | Kyoto University |
| Journal website | www.tandfonline.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
cells. We have begun to understand the molecular mechanisms of T cell exhaustion and early memory formation, and the clinical application of converting exhausted T cells to rejuvenated early memory T cells is the goal of our study.
The treatment of rheumatoid arthritis (RA) is now entering a new era, the era of Janus kinase (JAK) inhibitors. JAK inhibitors target multiple cytokines including IL-6 and exhibit a beneficial treatment effect in patients with RA and inadequate response to conventional synthetic or biologic disease-modifying anti-rheumatic drugs. Since the treatment effect of JAK inhibitors is…
Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease that develops in genetically susceptible individuals in response to environmental factors. SLE and primary immunodeficiency disease (PID) share some clinical manifestations in that certain PIDs present with autoimmune phenomena. Patients with SLE become susceptible to infection via three pathways. First, SLE and PID share some…
By proteomic screening of sera obtained from patients with rheumatoid arthritis (RA), we previously identified leucine rich α2 glycoprotein (LRG) as a possible marker for inflammation. Unlike C-reactive protein (CRP), a biomarker widely used to evaluate inflammation, LRG is induced not only by IL-6 but also by other proinflammatory cytokines. In addition, LRG is upregulated…
Difficult-to-treat rheumatoid arthritis (D2T RA) is a multifactorial condition in which disease activity of RA persists despite consecutive treatment with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). To evaluate the prevalence and predictive risk factors of D2T RA in our institution, a single-center, retrospective study was conducted. Medical records of RA patients, who visited…
